Stockscreener 앱 받기
17.55
0.80%
0.14
시간 외 거래:
17.55
전일 마감가:
$17.41
열려 있는:
$17.465
하루 거래량:
1.04M
Relative Volume:
0.50
시가총액:
$2.90B
수익:
-
순이익/손실:
$-446.21M
주가수익비율:
-4.9529
EPS:
-3.5434
순현금흐름:
$-423.92M
1주 성능:
-7.14%
1개월 성능:
-3.20%
6개월 성능:
-22.28%
1년 성능:
+48.85%
1일 변동 폭
$17.29
$17.91
1주일 범위
$17.29
$19.48
52주 변동 폭
$8.06
$25.00
다인 테라 Stock (DYN) Company Profile
명칭
Dyne Therapeutics Inc
전화
(781) 786-8230
주소
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
17.55 | 3.00B | 0 | -446.21M | -423.92M | -3.5434 |
VRTX
Vertex Pharmaceuticals Inc
|
427.38 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
707.06 | 76.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
781.72 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.49 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
295.27 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
다인 테라 Stock (DYN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-10 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-10-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-08-25 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | 개시 | Bernstein | Mkt Perform |
| 2025-06-11 | 재개 | Raymond James | Outperform |
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-05-29 | 개시 | Evercore ISI | Outperform |
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-13 | 개시 | Robert W. Baird | Outperform |
| 2024-11-26 | 개시 | RBC Capital Mkts | Outperform |
| 2024-10-24 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-05-21 | 재확인 | Chardan Capital Markets | Buy |
| 2024-04-30 | 개시 | Morgan Stanley | Overweight |
| 2024-02-20 | 개시 | H.C. Wainwright | Buy |
| 2023-02-27 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | 개시 | Oppenheimer | Outperform |
| 2023-01-26 | 개시 | Guggenheim | Buy |
| 2022-07-20 | 개시 | Chardan Capital Markets | Buy |
| 2022-07-12 | 개시 | Raymond James | Outperform |
| 2020-10-12 | 개시 | JP Morgan | Overweight |
| 2020-10-12 | 개시 | Jefferies | Buy |
| 2020-10-12 | 개시 | Piper Sandler | Overweight |
| 2020-10-12 | 개시 | Stifel | Buy |
모두보기
다인 테라 주식(DYN)의 최신 뉴스
Dyne therapeutics director Jason Rhodes sells $4.18m in stock - Investing.com
Atlas Venture funds tied to Dyne (DYN) director sell 227,337 shares - Stock Titan
MSN Money - MSN
Could Dyne Therapeutics (DYN) Turn Its FORCE Platform Into a Broader Neurology Franchise? - simplywall.st
Dyne Therapeutics earnings up next: DMD launch path in focus By Investing.com - Investing.com India
Dyne Therapeutics earnings up next: DMD launch path in focus - Investing.com
Facioscapulohumeral Muscular Dystrophy Market: Pharma Pipeline Fuels Rapid Expansion – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics - Barchart
Facioscapulohumeral Muscular Dystrophy Market: Pharma - openPR.com
DYN SEC FilingsDyne Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Director at Dyne Therapeutics (DYN) makes bona fide gift of 53,625 shares - Stock Titan
Dyne Therapeutics Insider Sold Shares Worth $7,101,120, According to a Recent SEC Filing - marketscreener.com
Dyne therapeutics director Jason Rhodes sells $7.1m in stock By Investing.com - Investing.com South Africa
Dyne Therapeutics(DYN.US) Director Sells US$7.1 Million in Common Stock - Moomoo
Dyne therapeutics director Jason Rhodes sells $7.1m in stock - Investing.com
[Form 4] Dyne Therapeutics, Inc. Insider Trading Activity - Stock Titan
Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting - The Manila Times
[144] Dyne Therapeutics, Inc. SEC Filing - Stock Titan
Dyne Therapeutics Announces Upcoming Presentation - GlobeNewswire
Dyne Therapeutics (DYN) Stifel 2026 Virtual CNS Forum Summary - Quartr
Dyne Therapeutics (DYN) Proxy filing Summary - Quartr
Dyne Therapeutics (DYN) TD Cowen 46th Annual Health Care Conference Summary - Quartr
Dyne Therapeutics director Kersten sells $219k in company stock - Investing.com
Dyne Therapeutics director Kersten sells $219k in company stock By Investing.com - Investing.com India
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 - Investing News Network
[ARS] Dyne Therapeutics, Inc. SEC Filing - Stock Titan
Director-affiliated fund trims Dyne Therapeutics (DYN) stake in 10b5-1 sales - Stock Titan
Dyne Therapeutics (NASDAQ: DYN) sets 2026 virtual meeting, share increase vote - Stock Titan
Dyne used stock awards to hire 18 employees, covering 423,000 shares - Stock Titan
Jason Rhodes Sells 274,297 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 272,049 Shares of Stock - MarketBeat
Dyne therapeutics director Jason Rhodes sells $16.48m in shares By Investing.com - Investing.com South Africa
Dyne Therapeutics(DYN.US) Director Sells US$16.48 Million in Common Stock - Moomoo
Atlas Venture funds sell Dyne (DYN) shares under 10b5-1 plan - Stock Titan
Dyne therapeutics director Dirk Kersten sells $6.8m in shares By Investing.com - Investing.com Australia
Dyne therapeutics director Dirk Kersten sells $6.8m in shares - Investing.com UK
DYN (Nasdaq) Form 144: Atlas Venture groups report proposed sales totaling tens of thousands of shares - Stock Titan
Atlas Venture affiliates sell shares of DYN (Nasdaq: DYN) in Rule 144 notices - Stock Titan
Atlas Venture sells DYN stock (Nasdaq: DYN) — 142,571-share entry listed - Stock Titan
Atlas Venture entities sell DYN shares (NASDAQ: DYN) under Form 144 disclosure - Stock Titan
Director-linked fund trims 337K Dyne Therapeutics (DYN) shares under 10b5-1 plan - Stock Titan
H.C. Wainwright Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Dyne Therapeutics: De-Risked DMD Opportunity, Pivotal DM1 Readout, and Emerging M&A Appeal Support Buy Rating - TipRanks
H.C. Wainwright reiterates Dyne Therapeutics stock rating at buy By Investing.com - Investing.com Canada
다인 테라 (DYN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.67%
자본화:
|
볼륨(24시간):